Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.
This activity is supported by an educational grant from AstraZeneca.
“Medical Crossfire®: Clinical Updates on PARP inhibition and its Evolving Use in the Treatment of Cancers” is a live continuing medical and nursing education (CME/CE)-certified symposium to be held adjunct to the 34th Annual Miami Breast Cancer Conference®, a PER® Legacy International Conference.
Poly (ADP-ribose) polymerase (PARP) inhibitors have garnered a great deal of clinical interest as a means of treating a variety of human cancers, with several therapeutic options currently in late-stage clinical development. With recent advancements in the understanding of tumor-defining molecular changes, use of PARP inhibitors has been shown to be efficacious as a cytotoxic strategy in the treatment of patients with breast and other gynecologic cancers. Clinical trial evidence continues to accumulate at a rapid pace. The placement of this evidence in the context of changing treatment paradigms for patients with breast cancer requires informed discussion.
To that end, we are bringing together a panel of internationally recognized experts in breast cancer therapy to facilitate the exchange of ideas and explore best practices regarding the potential impact of PARP inhibitors on the treatment landscape. Faculty will cover several key topics, including:
The symposium will be held at the Fontainebleau Miami Beach on March 10 from 10:30AM–12:00PM. Please join us live in Miami to learn the latest and greatest state-of-the-art science around PARP inhibitor therapies, as well as the most up-to-date information on appropriate and optimal use of these agents.
This CME/CE-certified symposium will provide a valuable opportunity to enhance your knowledge of PARP inhibitor therapy and learn from leading clinicians. We look forward to seeing you!
This educational activity is intended for all attendees of the Miami Breast Cancer Conference®, which includes medical, radiation, and surgical oncologists whose primary practice focus is breast cancer. Participants will be primarily oncologists or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the treatment and management of breast cancer.
Upon completion of this activity, participants will be able to:
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018